Metabolic causes and prevention of ventricular fibrillation during acute coronary syndromes

American Journal of Medicine

Volumn 112, Issue 4, 2002, Pages 305-311

  Oliver, Michael F ^a,b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b Keepier Wharf   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL COENZYME A; ACYLCARNITINE; ADENOSINE; APOLIPOPROTEIN C2; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CATECHOLAMINE; CYCLIC AMP; GLUCOSE; HEPARIN; HYDROCORTISONE; INSULIN; LINOLEIC ACID; LIPOPROTEIN LIPASE; LIPOTROPIC AGENT; NICOTINIC ACID; NICOTINIC ACID DERIVATIVE; NORADRENALIN; OLEIC ACID; OMEGA 3 FATTY ACID; OXFENICINE; POTASSIUM; PROSTAGLANDIN; PROTAMINE SULFATE; RANOLAZINE; THROMBOXANE; TRIMETAZIDINE;

ADIPOSE TISSUE; BLOOD FLOW; CATECHOLAMINE RELEASE; DRUG ACTIVITY; DRUG EFFECT; ELECTRIC CONDUCTIVITY; ELECTROLYTE DISTURBANCE; FATTY ACID BLOOD LEVEL; FATTY ACID OXIDATION; GLUCOSE TRANSPORT; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE FIBRILLATION; HUMAN; INCIDENCE; INOTROPISM; LIPOLYSIS; MEMBRANE PERMEABILITY; NONHUMAN; NORADRENALIN RELEASE; OXYGEN CONSUMPTION; PRIORITY JOURNAL; REVIEW;

ANIMALS; CATECHOLAMINES; ENERGY METABOLISM; FATTY ACIDS, NONESTERIFIED; GLUCOSE; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIUM; OXYGEN CONSUMPTION; VENTRICULAR FIBRILLATION;

EID: 0036121544     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(01)01104-4     Document Type: Review

References (56)

1. Sudden cardiac death: Epidemiology, transient risk, and intervention assessment
2. Ventricular fibrillation complicating acute myocardial infarction
3. Electropharmacological control of cardiac arrhythmias: To delay conduction or to prolong refractoriness
4. Dispersion of 'refractoriness' in noninfarcted myocardium of patients with ventricular tachycardia or ventricular fibrillation after myocardial infarction
5. 1967-1997: Thirty years of cardiac arrhythmias
6. A decade of clinical trials: CAST to AVID
7. Metabolic derangement in ischemic heart disease and its therapeutic control
8. Modulation of responses to myocardial ischemia: Metabolic features of myocardial stunning, hibernation, and ischemic preconditioning
9. Initial metabolic and hormonal response to acute myocardial infarction
10. Free noradrenaline and adrenaline excretion in relation to clinical syndromes following myocardial infarction
11. Serum-free-fatty-acids after acute myocardial infarction and cerebral vascular occlusion
12. Metabolism of free fatty acids, glucose and catecholamines in acute myocardial infarction
13. Metabolic responses of the heart in acute myocardial infarction in man
14. Relationship between carbohydrate and lipid metabolism and the energy balance of the heart
15. Serum lipoprotein patterns in coronary sclerosis and associated conditions
16. Relation between serum free fatty acids and arrhythmias and death after acute myocardial infarction
17. Relation between plasma free fatty acids and arrhythmias within the first twelve hours of acute myocardial infarction
18. Circulating non-esterified fatty acid level as a predictive risk factor for sudden death in the population
19. A metabolic cause for arrhythmias during acute myocardial hypoxia
20. Arrhythmias following infusions of fatty acids
21. Free fatty acids, heparin and arrhythmias during experimental myocardial infarction
22. The effect of antilipolytic agents on cyclic AMP, free fatty acid and total catecholamine concentrations in plasma
23. Turnover of plasma glucose and free fatty acids in patients on the first day after acute myocardial infarction
24. Essential fuels for the heart and mechanical restitution
25. Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias
26. Optimizing cardiac energy metabolism: A new approach to treating ischaemic heart disease
27. The mechanism of the lipolytic action of catecholamines
28. Long-chain acylcarnitine increases intracellular Ca2+ and induces afterdepolarization in adult ventricular myocytes
29. Free fatty acid metabolism during myocardial ischemia and reperfusion
30. Effect of free fatty acids on myocardial functions and oxygen consumption in intact dogs
31. Metabolic aspects of rhythm disturbances
32. The transport and utilization of free fatty acid
33. Effect of palmitic acid and fatty acid binding protein on ventricular fibrillation threshold in the perfused rat heart
34. Relationship of epicardial ST segment elevation to the plasma free fatty acid/albumin ratio during coronary occlusion in dogs
35. The role of free fatty acids in the production of ventricular arrhythmias after acute coronary artery occlusion
36. Dietary lipid modulation of ventricular fibrillation threshold in the marmoset monkey
37. Prevention of sudden cardiac death by dietary pure ω-3 polyunsaturated fatty acids in dogs
38. Differential effects of various eicosanoids on the production or prevention of arrhythmias in cultured neonatal rat cardiac myocytes
39. Cardiac fatty acid metabolism and the induction of apoptosis
40. Fatty acid oxidation in the perfused ischemic heart
41. Metabolic approaches in ischaemic heart disease
42. β-blockers and sudden death
43. Cardioprotection with beta-adrenoceptor blockers. Does lipophilicity matter?
44. Trimetazidine inhibits fatty acid oxidation in the heart
45. Effects of ranolazine on ischemic threshold, coronary sinus blood flow and myocardial metabolism in coronary artery disease
46. Trimetazidine: A new concept in the treatment of angina. Comparison with propanolol in patients with stable angina
47. Metabolic modulation of acute myocardial infarction. The ECLA Glucose-Insulin-Potassium pilot trial
48. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus
49. Glucose-insulin-potassium (GIK) for acute myocardial infarction: A negative study with a positive value
50. Effect of myocardial ischaemia and antilipolytic agents on lipolysis and fatty acid metabolism in the in situ dog heart
51. Control of ventricular arrhythmias during myocardial infarction by anti-lipolytic treatment using a nicotinic acid analogue
52. Effect of inhibition of lipolysis on infarct size after experimental coronary artery occlusion
53. Effect of antilipolytic therapy on ST seg-ment elevation during myocardial ischaemia in man
54. Anti-lipolytic therapy in angina pectoris: Reduction of exercise-induced ST segment depression
55. Lipoprotein and hepatic lipase in lipoprotein metabolism
56. Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism